ArticleClinical and translational medicine2023
LEPRE1 shapes a non-flamed tumour immune landscape and predicts the prognosis in esophageal squamous cell carcinoma.
Meng Liu, Yu Ma, Yunquan Guo, Yue Ma, Xinxin Bao, Xiaomei Lu
Open access · goldAbstract readLetter
In one paragraphArticle in Clinical and translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 65% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors at 1 institution in 1 country.
Meng LiuState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China.
Yu MaDepartment of Clinical Laboratory, The Fourth People' Hospital of Urumqi, Xinjiang Uygur Autonomous Region, Urumqi, PR China.
Yunquan GuoState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China.
Yue MaDepartment of Pharmacy, Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China.
Xinxin BaoDepartment of Pharmacy, Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China.
Xiaomei LuClinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China.ORCID 0000-0001-7713-3774 Xinjiang Medical University · CN
Funding
Distinguished Young project of Natural Science Foundation of Xinjiang Uygur Autonomous Region 2022D01E76Key project of Xinjiang Uygur Autonomous Region Natural Science Foundation 2022D01D69leading talent project of scientific and technological innovation in Tianshan talents training plan of Xinjiang Uygur Autonomous Region 2022TSYCLJ0031National Natural Science Foundation of China 82260600State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund SKL-HIDCA-2019-14Youth Fund of Affiliated Tumor Hospital of Xinjiang medical University 2021YQ002
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Squamous CellEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaHumansPrognosis
Identifiers
PMID37997529
PMCPMC10667621
OpenAlexW4388979036
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390